Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-08-13
2008-12-02
Riley, Jezia (Department: 1637)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S001000, C536S023100, C536S025300
Reexamination Certificate
active
07459443
ABSTRACT:
This invention relates to a new method of synthesis of biologically active substances of determined structure directly in the cells of living organisms containing specific RNA or DNA molecules of determined sequence. The method is based on the hybridization of two or more oligomers bound with biologically inactive precursors of biologically active substances to specific RNA or DNA in vivo in the cells of living organisms. After hybridization of the oligomers to RNA or DNA the biologically inactive precursors bound to the 5′ and/or 3′ ends of the oligomers can interact with each other to make biologically active form of the substances. This changing of properties is due to chemical reactions which bind the biologically inactive precursors through a chemical bond into a biologically active form of the whole compound.
REFERENCES:
Walder et al, “Complementary carrier peptide synthesis etc.”; Proc. Nat. Acad. Sci. USA 1979 vol. 76, No. 1, p. 51-5.
Bruick et al, “Template-directed ligation of peptides to oligonucleotides”, Chem. Biol. 1996, vol. 3, No. 1, p. 49-56.
Visscher et al, “Template-directed synthesis etc.”, J. Mol. Evol. 1988, vol. 28, No. 1-2, p. 3-6.
Harlow et al, “Molecular cloning and in vitro expression etc.”, Mol. & Cell. Biol., vol. 5, No. 7, p. 1601-10.
The Merck Index, Abstract 2867, 1996, Dactinomycin.
Liou et al, “Antitumour agents LIV etc.”, J. Pharm. Sci. 1982, vol. 71, No. 7, p. 745-9.
Yoshimoto et al, “A new synthetic method etc.”, Tetrahedron Letters, vol. 24, 1983, p. 2779-80.
The Merck Index, Abstract 6836 (1996) Ochratoxins.
The Merck Index, Abstract 3703 (1996) Ergotamine.
The Merck Index, Abstract 387 (1996) Amanitin.
Uhlmann et al, “Antisense Oligonucleotides: A New Therapeutic Principle”, Chemical Reviews, vol. 90, No. 4, 1990, p. 543-584.
Monia et al, “Sequence-specific antitumour activity of a phosphorothioate etc.”, Proc. Natl. Acad. Sci. USA, vol. 93, (1996), p. 15481-84.
Flanagan et al, “Cellular penetration and antisense activity etc.”, Nature Biotechnology, vol. 17, 1999, p. 48-52.
Dean, “Functional genomics and target validation approaches etc.”, Current Opinion in Biotechnology, 2001, vol. 12, p. 622-625.
Eilberg William H.
Riley Jezia
LandOfFree
Synthesis of biologically active compounds in cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis of biologically active compounds in cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis of biologically active compounds in cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4047808